Summary
New warnings on hepatotoxicity risk and monitoring recommendations have been added to the Product Information for Veoza (fezolinetant).
We undertook a review after the pharmaceutical company Astellas notified us of an analysis of their global safety database, including post-marketing cases of hepatotoxicity. We then worked with them to update the Australian Product Information.
Fezolinetant is used to treat moderate to severe vasomotor symptoms associated with menopause. These symptoms include sudden feelings of warmth (hot flashes) and sweating (night sweats) that occur when the body's temperature regulation system malfunctions.
What health professionals should do
Be alert to the new advice as described in ‘Updates to the PI’ below.
Advise patients to discontinue Veoza immediately and seek medical attention, including hepatic laboratory tests, if they experience signs or symptoms that may suggest hepatotoxicity. Such symptoms include new-onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale faeces, dark urine or abdominal pain.
Perform follow-up evaluation of hepatic function monthly for the first 3 months after initiating Veoza, then at 6 months and 9 months, and thereafter periodically based on clinical judgement.
Updates to the PI
The following updates have been made to the Australian Product Information:
4.2 Dose and method of administration
Perform baseline hepatic laboratory tests to evaluate for hepatic function and injury [including serum alanine aminotransferase (ALT), serum aspartate aminotransferase (AST), serum alkaline phosphatase (ALP) and serum bilirubin (total and direct)] before initiating treatment with Veoza. Do not start Veoza if ALT or AST is ≥ 2 x ULN or if the total bilirubin is ≥ 2 x ULN for the evaluating laboratory.
While using Veoza, perform follow-up hepatic laboratory tests monthly for the first 3 months, at 6 months and 9 months after initiation of therapy.
Advise patients to discontinue Veoza immediately and seek medical attention including hepatic laboratory tests if they experience signs or symptoms that may suggest liver injury (see section 4.4 Special warnings and precautions for use).
4.4 Special warnings and precautions for use
In the post-marketing setting, cases of serious but reversible hepatotoxicity have been reported within 40 days of treatment. Patients have experienced transaminase elevations (greater than 10 times the ULN) with concurrent elevations in bilirubin and/or alkaline phosphatase (ALP), sometimes associated with signs or symptoms such as fatigue, pruritus, jaundice, dark urine or abdominal pain.
Evaluate hepatic function (ALT, AST, ALP and bilirubin) before initiating therapy. Do not initiate Veoza if ALT or AST is equal to or exceeds 2 times the ULN or if the total bilirubin is elevated (e.g., equal to or exceeds 2 times the ULN).
Patients should discontinue Veoza immediately and seek medical attention, including hepatic laboratory tests, if they experience signs or symptoms that may suggest hepatotoxicity such as new-onset fatigue, decreased appetite, nausea, vomiting, pruritus, jaundice, pale faeces, dark urine or abdominal pain.
Perform follow-up evaluation of hepatic function monthly for the first 3 months, at 6 months and 9 months after initiating Veoza, and thereafter periodically based on clinical judgement.
Discontinue Veoza if:
- transaminase elevations are greater than 5 times the ULN
- transaminase elevations are greater than 3 times the ULN and the total bilirubin level is greater than 2 times the ULN.
Monitoring of liver function tests should continue until they have normalised, and other causes of liver injury should be excluded.
Section 4.8 Adverse effects (undesirable effects)
Addition of the following adverse reactions:
- Aspartate aminotransferase (AST) increased with a frequency of common.
- Hepatotoxicity with a frequency of not known.
Description of selected adverse reactions:
Hepatotoxicity
Serious cases of drug-induced hepatotoxicity occurred within 40 days of starting Veoza. Patients experienced elevated transaminases (up to 50 x ULN at peak elevation), elevated alkaline phosphatase (up to 4 x ULN at peak elevation) and bilirubin (up to 5 x ULN at peak elevation), coupled with symptoms of fatigue, nausea, pruritus, jaundice, pale faeces and dark urine. After discontinuation of Veoza, these abnormalities gradually resolved.
Adverse events reported to us
A search of our database of adverse event notifications on 17 September 2025 found a total of 14 reports for fezolinetant with any adverse event. Of these, there was 1 case of alanine aminotransferase increased, 1 case of liver function test increased and 1 case of liver function test abnormal.
Further reading
Other regulatory authorities have also published around the risk of hepatotoxicity with fezolinetant:
- FDA Drug Safety Communication - FDA Adds Warning About Rare Occurrence of Serious Liver Injury with Use of Veozah (fezolinetant) for Hot Flashes Due to Menopause. Stop Medicine if Signs and Symptoms of Liver Injury Occur - Drug Safety Communication.
- EMA direct healthcare professional communication - Veoza (fezolinetant): risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment
- MHRA drug safety update - Fezolinetant▼(Veoza): risk of liver injury; new recommendations to minimise risk
Disclaimer
Medicine Safety Updates are aimed at health professionals. They are intended to provide practical information to health professionals on medicine safety, including emerging safety issues. The information in Medicine Safety Updates is necessarily general and is not intended to be a substitute for a health professional's judgment in each case, taking into account the individual circumstances of their patients. Reasonable care has been taken to ensure that the information is accurate and complete at the time of publication. The Australian Government gives no warranty that the information in this document is accurate or complete and shall not be liable for any loss whatsoever due to negligence or otherwise arising from the use of or reliance on this document.
© Commonwealth of Australia 2025
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to tga.copyright@tga.gov.au.
For the latest safety information from us, subscribe to the TGA Safety Information email list via our website.
For correspondence or further information about Medicines Safety Update visit Contact us.